JAGX - Jaguar Health, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3140
-0.0090 (-2.79%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.3230
Open0.3281
Bid0.300 x 2900
Ask0.340 x 1300
Day's Range0.3005 - 0.3400
52 Week Range0.2840 - 6.6000
Volume198,460
Avg. Volume2,011,717
Market Cap8.569M
Beta (3Y Monthly)-0.52
PE Ratio (TTM)N/A
EPS (TTM)-4.279
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • ACCESSWIRE10 days ago

    Jaguar Health, Inc. Engages T.R. Winston & Company to Advise on Collaboration, Licensing and Development Activities Related to Mytesi and Crofelemer

    SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2018 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that it has engaged T.R. Winston & Company, LLC (''T.R. Winston'') to provide strategic advice with respect to collaboration, licensing and development activities in support of Mytesi® and crofelemer. Mytesi is FDA-approved for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS who are on antiretroviral therapy.

  • ACCESSWIRElast month

    Jaguar Health, Inc. Reports Third-Quarter 2018 Results

    SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today reported third quarter 2018 results and issued the following highlights. Mytesi Net Product Revenue: Mytesi gross sales in the third quarter of 2018 were approximately $1.6 million, and Mytesi net sales were approximately $1.1 million, an increase of 242% and 154% of gross and net sales, respectively, over the third quarter of 2017.

  • ACCESSWIRElast month

    Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th

    Company to Host Conference Call Thursday, November 15, 2018 at 8:00 a.m. Eastern Time to Review Q3 Results and Provide Updates Regarding Mytesi ® Commercial, Educational & Product Development Activities ...

  • ACCESSWIRE2 months ago

    The Brilliance Behind a Global Operator of Crypto Exchanges BitMax: Understanding the Trans-Fee Mining Model

    NEW YORK, NY / ACCESSWIRE / October 29, 2018 / As the demand for digital and crypto-assets grows, the long-term success of trading platforms is dependent on several factors including architecture design, ...

  • ACCESSWIRE2 months ago

    Jaguar Health, Inc. Expects to File Third-Quarter 2018 Financial Results November 14th

    SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that it expects to file its third-quarter 2018 financial results on Wednesday, November 14, 2018 on Form 10-Q with the U.S. Securities and Exchange Commission. The Company will host a conference call on Thursday, November 15, 2018 at 8:00 a.m. Eastern Time to discuss third-quarter results as well as current and planned commercial, educational and product development activities related to Mytesi (crofelemer), Jaguar's first-in-class, FDA-approved anti-secretory human prescription drug.

  • ACCESSWIRE2 months ago

    Jaguar Health, Inc. to Host Investor Meetings at Dawson James Small Cap Growth Conference Tuesday, October 30, 2018 in Jupiter, Florida

    SAN FRANCISCO, CA / ACCESSWIRE / October 24, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, ...

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE2 months ago

    Jaguar Health Announces Pricing of $9 Million Underwritten Public Offering

    SAN FRANCISCO, CA / ACCESSWIRE / October 2, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the pricing of an underwritten public offering of 15,000,001 total shares of its common stock (or common stock equivalents), at a public offering price of $0.60 per share, for gross proceeds of approximately $9.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Jaguar. Jaguar has granted the underwriter a 30-day option to purchase up to an aggregate of 2,250,000 additional shares of its common stock to cover over-allotments, if any.

  • ACCESSWIRE3 months ago

    These Biotech and Cannabis Stocks Are Skyrocketing

    HENDERSON, NV / ACCESSWIRE / September 26, 2018 / A fascinating biotechnology firm PPCB (Propanc Biopharma, Inc.) erupted for over 7000% in the last month going from a low of $0.0039 to a high of over ...

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Jaguar Health and TG Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 26, 2018 / U.S. equities were mixed on Tuesday as concerns of a potential trade war linger and investors look forward to details from the upcoming Fed monetary policy ...

  • MarketWatch3 months ago

    Jaguar Health's stock triples after licensing deal, has been halted 13 times for volatility

    Shares of Jaguar Health Inc. more than tripled in extremely volatile trade Tuesday, after the pharmaceutical company announced a distribution, license and supply agreement with Canada-based specialty pharmaceutical company Knight Therapeutics Inc. , in which Jaguar could receive up to $18 million in milestone payments from Knight. Jaguar stock, which closed Monday at 65 cents, had been up as much as 285% at its intraday high of $2.50 before paring some gains, to be up 206% in afternoon trade. Volume spiked to 38.9 million shares, compared with the full-day average of about 150,000 shares. The stock has been temporarily halted no less than 13 times for volatility throughout the day. The agreement with Knight grants Knight the exclusive right to commercialize Jaguar's Mytesi for the treatment of noninfectious diarrhea and related products in Canada and Israel, and the right to negotiate commercialization in Latin America. Despite the rally, Jaguar's stock was still down 5.1% year to date, while Knight shares have slipped 0.2% and the S&P 500 has gained 9.1%.

  • GlobeNewswire3 months ago

    Knight Therapeutics and Jaguar Health Announce Strategic Partnership

    MONTREAL and SAN FRANCISCO, Sept. 24, 2018 -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian-based specialty pharmaceutical company focused on acquiring,.

  • ACCESSWIRE3 months ago

    Knight Therapeutics and Jaguar Health Announce Strategic Partnership

    Knight Receives License to Mytesi ® and Related Products in Canada and Israel MONTREAL, QC and SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2018 / Knight Therapeutics Inc. (TSX: GUD) (" Knight"), ...

  • ACCESSWIRE5 months ago

    New Analysis of Data in Over 21,000 People Living with HIV Shows Diarrhea Continues to be an Issue and Has Not Declined Significantly Over Time

    SAN FRANCISCO, CA / ACCESSWIRE / July 24, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (Jaguar), announced today the results of an analysis conducted to examine whether the rate of HIV-associated diarrhea has changed over time. The analysis of data, sourced from the National Institutes of Health (NIH) clinicaltrials.gov database, revealed that 18% of HIV patients experience diarrhea and the rates have not declined significantly over time. The analysis includes data from 38 U.S. clinical trials from 2008-2016 in more than 21,000 patients.

  • ACCESSWIRE5 months ago

    Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration. Gains were broad based as six out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: GlycoMimetics Inc. (NASDAQ: GLYC), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).

  • ACCESSWIRE5 months ago

    Napo Pharmaceuticals to Present New Data at the 22nd International AIDS 2018 Conference

    Presentation Will Cover New Data on the Incidence and Prevalence of Diarrhea in HIV Clinical Trials in the Recent Post-Combined Antiretroviral Therapy (cART) Era SAN FRANCISCO, CA / ACCESSWIRE / July 16, ...

  • ACCESSWIRE5 months ago

    Jaguar Health, Inc. Provides Second Quarter 2018 Financial Updates

    SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced financial updates today for the second quarter ended June 30, 2018. Achieved 125% growth in gross sales of Mytesi for the first six-months of 2018 versus the same period in 2017, and 120% growth in gross sales of Mytesi in the second quarter of 2018 compared to the second quarter of 2017. Continued expansion of the U.S. Napo direct sales organization through the hire of sales representatives with extensive HIV-related experience.

  • ACCESSWIRE6 months ago

    Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product

    SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (Jaguar), today announced that it has entered into an agreement (the Agreement) with RedHill Biopharma Ltd. (RedHill) (RDHL), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, to establish a U.S. co-promotion program for Mytesi® (crofelemer 125 mg delayed-release tablets), Napo's FDA-approved drug, for the current approved indication. Mytesi is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

  • ACCESSWIRE6 months ago

    Jaguar Health Appoints Pharmaceutical Industry Veteran David MacNaughtan to Board of Directors

    SAN FRANCISCO, CA / ACCESSWIRE / June 20, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has appointed David MacNaughtan, an executive with more than 25 years of biopharmaceutical industry experience with roles spanning financing, venture capital, royalty investing, business development, and process development, to the Company's board of directors. Most recently, Mr. MacNaughtan led the intellectual property investing strategy at CPPIB Credit Investments Inc., a wholly-owned subsidiary of the Canada Pension Plan Investment Board, for eight years, focused on the acquisition and securitization of pharmaceutical royalty streams.

  • ACCESSWIRE6 months ago

    Jaguar Health Appoints Senior Commercial Pharmaceutical Executive Greg Divis to Board of Directors

    SAN FRANCISCO, CA / ACCESSWIRE / June 18, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has appointed Greg Divis, an executive with more than 28 years of direct operating and global leadership experience in specialty pharmaceuticals, to the Company's board of directors. Mr. Divis currently serves as the Chief Operating Officer of Avadel Pharmaceuticals, an emerging branded specialty pharmaceutical company he joined in 2017.

  • ACCESSWIRE6 months ago

    Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar

    Stock Research Monitor: JAGX, JAZZ, and LJPC LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration . On Thursday, June 14, ...